A phase III, randomized, open label trial of Lenalidomide/Dexamethasone with or without Elotuzumab in subjects with previously untreated Multiple Myeloma (#432)
Laufzeit: 01.01.2012 - 31.12.2019
imported
Kurzfassung
Phase III study
